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Abstract: Recognising the burden helminth infections
impose on human populations, and particularly the poor,
major intervention programmes have been launched to
control onchocerciasis, lymphatic filariasis, soil-transmit-
ted helminthiases, schistosomiasis, and cysticercosis. The
Disease Reference Group on Helminth Infections (DRG4),
established in 2009 by the Special Programme for
Research and Training in Tropical Diseases (TDR), was
given the mandate to review helminthiases research and
identify research priorities and gaps. A summary of
current helminth control initiatives is presented and
available tools are described. Most of these programmes
are highly dependent on mass drug administration (MDA)
of anthelmintic drugs (donated or available at low cost)
and require annual or biannual treatment of large
numbers of at-risk populations, over prolonged periods
of time. The continuation of prolonged MDA with a
limited number of anthelmintics greatly increases the
probability that drug resistance will develop, which would
raise serious problems for continuation of control and the
achievement of elimination. Most initiatives have focussed
on a single type of helminth infection, but recognition of
co-endemicity and polyparasitism is leading to more
integration of control. An understanding of the implica-
tions of control integration for implementation, treatment
coverage, combination of pharmaceuticals, and monitor-
ing is needed. To achieve the goals of morbidity reduction
or elimination of infection, novel tools need to be
developed, including more efficacious drugs, vaccines,
and/or antivectorial agents, new diagnostics for infection
and assessment of drug efficacy, and markers for possible
anthelmintic resistance. In addition, there is a need for the
development of new formulations of some existing
anthelmintics (e.g., paediatric formulations). To achieve
ultimate elimination of helminth parasites, treatments for
the above mentioned helminthiases, and for taeniasis and
food-borne trematodiases, will need to be integrated with
monitoring, education, sanitation, access to health
services, and where appropriate, vector control or
reduction of the parasite reservoir in alternative hosts.
Based on an analysis of current knowledge gaps and
identification of priorities, a research and development
agenda for intervention tools considered necessary for
control and elimination of human helminthiases is
presented, and the challenges to be confronted are
discussed.
Introduction
The increasing recognition of the burden imposed by human
helminthiases has led to the implementation of large-scale control
and elimination programmes. In the accompanying review of this
collection (‘‘The Problem of Helminthiases’’), Lustigman et al. [1]
summarise the historical development and remit of such initiatives.
In this paper, Table 1 presents the various programmes’ aims and
strategies, as well as the helminths they target. Although these
programmes recognise the importance of ancillary strategies such
as environmental improvement, increased hygiene, and sustained
socioeconomic development, targeted mass drug administration
(MDA) has become their mainstay. The drugs (anthelmintics)
involved are in some cases donated by pharmaceutical companies
(e.g., ivermectin [IVM] by Merck & Co. for onchocerciasis and
lymphatic filariasis [LF]; albendazole [ABZ] by GlaxoSmithKline
for LF, and soil-transmitted helminthiases [STHs] in Africa;
mebendazole [MBZ] for STHs, by Johnson & Johnson), and in
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www.plosntds.org 2 April 2012 | Volume 6 | Issue 4 | e1549other cases are affordable as generic preparations (e.g., prazi-
quantel [PZQ] for schistosomiasis; diethylcarbamazine [DEC] for
LF). In general, the anthelmintic drugs adopted by the control
programmes are administered as a single dose at regular intervals,
generally yearly or twice yearly. Used in this way, they are usually
safe for mass treatment of human populations and are moderately
effective in terms of reducing the intensity of infection and, in some
cases, curing a proportion of infected individuals.
In the last decade, epidemiological studies in areas under
control have demonstrated successes in addressing human
helminthiases. The latter include infections by nematodes
(roundworms), and trematodes and cestodes (flatworms). Among
the roundworms, this review focuses on filarial infections
(particularly those caused by Onchocerca volvulus and Wuchereria
bancrofti), as well as on the most common soil-transmitted helminth
infections caused by Ascaris lumbricoides (roundworm), Trichuris
trichiura (whipworm), Necator americanus, and Ancylostoma duodenale
(hookworms). Among the trematode infections, we focus on those
caused by Schistosoma species and the food-borne trematodiases,
and among the cestode infections, we address some issues related
to taeniasis and (neuro)cysticercosis (caused by Taenia solium).
However, mass chemotherapy as a control strategy has
challenges, including optimising community involvement and
participation, and monitoring and evaluating the effectiveness and
impact of MDA. While global funding for these programmes has
increased in recent years, enthusiasm tends to wane after the initial
successes (which are invariably largest at the beginning), and
‘‘donor fatigue’’ becomes a risk. Other issues include the fact that
the arsenal of available drugs is limited, with very little
development of new drugs specifically targeted to human
helminthiases. This makes the existing control programmes highly
vulnerable should anthelmintic resistance develop and spread, as is
possible following years of MDA [2,3]. Billions of doses of
anthelmintics have been administered to infected and exposed
individuals, in some cases for prolonged periods, and have
undoubtedly yielded health benefits for the treated populations.
However, helminth infections persist in their host populations and
show resilience to control. Some of the factors responsible for the
persistence of human helminthiases as a public health problem,
despite the many initiatives that have been launched for their
control, are discussed by Lustigman et al. [1]
In this review, and based on deliberations by the Disease
Reference Group on Helminth Infections (DRG4), established in
2009 by the Special Programme for Research and Training in
Tropical Diseases (TDR), a summary of the current strategies and
available tools for the control of single helminth infections is
presented, followed by a discussion of the challenges posed by
integrated control in the face of co-endemicity and polyparasitism
with more than one infection. A research and development agenda
is presented that addresses the need for novel intervention tools in
addition to the employment of existing ones, as well as the
requirement for monitoring and evaluation (M&E) of the
interventions, the design of surveillance systems, and the
development of better assays to detect promptly decreased
intervention efficacy and emerging anthelmintic resistance. A
summary of key points for successful intervention are presented in
Box 1. This agenda and its challenges are discussed below in the
context of morbidity control and elimination programmes.
Community and Individual Interventions
Although the goal of some programmes (Table 1) has been that
of morbidity control and elimination of the public health burden
(STHs, schistosomiasis, and onchocerciasis in Africa for the most
part), others aim at interruption of transmission and eventual
elimination of the parasite reservoir (LF, onchocerciasis through
vector control/elimination in Africa, onchocerciasis in Latin
America, dracunculiasis). However, most of the helminth diseases
cause chronic and often sub-clinical morbidity. Therefore,
intervention is often at the community level aimed at reducing
both morbidity and transmission in the community. However,
treated people are subject to reinfection when the environmental
source or vector/reservoir is not sufficiently reduced. Further, as
discussed below, the available drugs are not reliably curative. With
community-based intervention, the expectation is that the impact
of treatment will be sustainable because the burden of infective
stages in the environment will be progressively reduced by
repeated rounds of treatment.
Anthelmintic treatment can be aimed at particular occupational
or age groups that are thought to represent those most at risk of
acquiring heavy infection and subsequently developing severe
Box 1. Summary Points for Control
Interventions against Helminthiases
N Major intervention programmes have been launched
against onchocerciasis, LF, STHs, and schistosomiasis,
which are mostly dependent on MDA of anthelmintics
and require annual or biannual treatment of large
numbers of populations at risk. The implementation of
these programmes has been aided by drug donation
(ivermectin, albendazole, mebendazole), and drug af-
fordability (diethylcarbamazine, praziquantel)
N Co-endemicity and polyparasitism are common and
there are advantages in integrating intervention efforts
for different diseases. This requires an understanding of
the implications of integration of programmes, effects
on treatment coverage, and combination of suitable
pharmaceuticals
N The efficacy of current anthelmintics ranges from
moderate to relatively high, and some drugs do not kill
the adult worms but reduce reproduction and thus
transmission
N Some programmes aim at reducing morbidity and
transmission (preventative chemotherapy), whilst others
aim at parasite elimination, requiring repeated treat-
ments over many years to reduce or suppress environ-
mental contamination or vector/intermediate host in-
fection with transmission stages. The continued and
prolonged MDA with the same limited number of
anthelmintic monotherapies over many years greatly
increases the probability that drug resistance will
develop, raising concerns about the sustainability of
control and the achievement of elimination
N For elimination of these diseases, there is a need for the
development of: 1) better anthelmintics and new
formulations (e.g., paediatric formulations); 2) additional
control tools such as vaccines and their integration into
current strategies; 3) complementation of MDA with
vector control where possible; 4) new monitoring tools
with which to detect low level infections that may play a
role in maintaining transmission; 5) tools to understand
and monitor anthelmintic resistance
N To achieve ultimate elimination of human helminthiases,
MDA and individual drug treatments need to be
integrated with education, sanitation, environmental
improvement, adequate monitoring and surveillance,
and other available and novel control tools
www.plosntds.org 3 April 2012 | Volume 6 | Issue 4 | e1549morbidity. This is, for instance, the basis for school-based health
programmes aimed at deworming children of STHs and
schistosomiasis. In this target population, treatment is adminis-
tered to all individuals regardless of whether or not they are
patently infected. In areas of substantial endemicity, and according
to infection prevalence thresholds, community (mass) treatment is
recommended. Other strategies include mass screen and treat
(targeting selective treatment to those with patent and detectable
infection at the point of screening), or treating individual cases in
clinical as opposed to community settings. The adoption of such
treatment modalities may also depend on the stage of the control
programme, with MDA implemented at its commencement, and
selective treatment used in mopping-up phases.
Optimum treatment coverage with MDA is required for the
success of control and elimination programmes for helminth
infections. Mathematical models predict, and experience confirms,
that population coverage is a key determinant of the success of
such programmes. Thus, there is a need to evaluate the
compliance of the population participating in such programmes
over the years. The use of the term ‘‘therapeutic coverage’’ (the
proportion of the population treated) implies that the persons who
receive the drugs are actually taking them (i.e., they are
compliant), but in some countries, a gap between coverage and
compliance has been observed, as for instance in the case of LF
[4–6], and there may be systematic non-compliance (with the
same group of people failing to take the drugs). The contribution
of non-compliant persons to transmission has not been quantified
for most of the infections, but systematic non-compliance may
represent a potential threat for helminth control or elimination.
Furthermore, the sustainability of the required long-term treat-
ment programmes also raises issues of compliance related to
possible population fatigue, waning interest of community drug
distributors, and continuing funding by external donors, as the
original funds that initiated the treatment-based control pro-
grammes may be time-limited.
Anthelmintic treatment of symptomatic individuals with
hookworm, schistosomiasis, or neurocysticercosis can have marked
effects in reducing morbidity. Therefore, interventions for the
control of STHs and schistosome infections involve also chemo-
therapy of individuals. The control of food-borne trematodiases is
usually on an individual patient basis and not via large-scale
MDA. However, MDA with triclabendazole has recently com-
menced for fasciolasis. The control of taeniasis/cysticercosis is
undertaken on an individual basis following case detection, and
more recently by MDA with niclosamide or PZQ. In addition,
oxfendazole treatment of pigs, as intermediate hosts, complements
human taeniasis treatment and can decrease the time to
elimination [7,8].
Current Intervention Tools
Vector Control
Control of the vectors (including snail hosts) has been partially
successful for onchocerciasis, particularly in West Africa [9],
schistosomiasis in China [10], and more locally in some LF foci
(e.g., in Zanzibar [11], and India [12]) and can be a valuable
adjunct to other forms of parasite control. However, vector control
currently is not the primary intervention used against helminthi-
ases, and we have considered it as beyond the scope of this review.
Drugs
The majority of the control programmes listed in Table 1 rely
heavily on anthelmintics, and overall have resulted in significant
reductions in the prevalence and intensity of infection and
morbidity in some endemic areas [13–16]. The drugs used for
each targeted helminth infection are detailed below. Interruption
of transmission for some infections, leading towards local
elimination, has been reported [17–21]. One reason for this
heavy reliance on chemotherapy is because the drugs are donated
for some programmes by pharmaceutical companies, or their cost
has become affordable [22]. This intervention has been referred to
as ‘‘a rapid-impact package’’ because the impact of anthelmintic
treatment on parasite populations is proportionally largest at the
beginning of the intervention [23]. However, long-term sustain-
ability of the benefits accrued will critically depend on altering the
environmental components that facilitate transmission. Large-scale
elimination of the infection reservoir will depend on improving
sanitation and drainage, providing access to clean water, disposing
adequately of excreta and solid waste, promoting access to health
services for diagnosis and treatment, and facilitating adequate
housing and health education [24,25]. The issues concerning the
environmental and social ecology of human helminthiases are
discussed in the accompanying review by Gazzinelli et al. [26].
Moreover, in programmes where the objective is eliminating the
infection reservoir, treatment will be aimed to include the largest
number of people with the highest possible coverage for as long as
autochthonous transmission persists. This may impose strong
selection pressures upon parasite genomes, affecting genetic
diversity and favouring drug-resistant strains.
Current Control Programmes and Ongoing
Challenges
Filarial Infections
Tens of millions of people living in hyper- and mesoendemic
areas in Africa and in hypoendemic areas in Latin America are
receiving annual or semi-annual treatment for onchocerciasis with
IVM, while hundreds of millions of people across the world are
receiving annual treatment for LF. For onchocerciasis, the only
drug available for safe mass treatment is IVM. For LF, mass
chemotherapy uses DEC plus ABZ or DEC alone, outside of sub-
Saharan Africa, where IVM plus ABZ is used because of
contraindications for DEC in patients infected with O. volvulus.
IVM is highly microfilaricidal and also suppresses adult worm
reproduction (production of new microfilariae [mf]) for several
months in onchocerciasis [27] and LF [28]. DEC is also highly
microfilaricidal, suppresses adult worm reproduction for several
months, and kills a fraction of the adult lymphatic filariae. ABZ
appears to contribute to the suppression of adult worm
reproduction [29]. It also has effects on STHs (see below),
producing possible ancillary benefits in those treated. Vector
abatement can also reduce transmission and support the control of
onchocerciasis [30,31] and LF [32,33].
In Africa, drug distribution is delivered by a system named
Community Directed Treatment with Ivermectin (CDTI). For the
control of onchocerciasis and LF, intervention is largely dependent
on MDA where communities at risk are treated in order to reduce
morbidity and parasite transmission. In the case of LF, topical
treatment of individuals with affected limbs or other organs with
antiseptic washes should be used as an adjunct treatment to reduce
morbidity [34]. These mass chemotherapy programmes aim to
achieve a high level of coverage (65%–90%) of the eligible
population. Coverage comprises two components, geographical
coverage (percentage of communities treated in an endemic area)
and therapeutic coverage (percentage of the population treated in
a community). Individuals who are eligible but do not present for
treatment are considered as non-compliant. In addition, individ-
uals who present for treatment, are given the medication, but do
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compliant. A recent study of treatment for LF in India found
30.6% of people given medication actually did not take the
anthelmintics [35]. In another drug compliance study among
adults it was revealed that although most long-term residents
included in the study, in Uganda, had been offered treatment at
least in the 4 years of the study, the actual take up of drugs
(proportion of the population who are offered free drugs who
actually ingest the medication) for schistosomiasis and STHs
varied considerably (0%–100%) from one district to another and
often also within districts [36]. The specific reasons why MDA
succeeded in some locations and faltered in others related to local
dynamics. Both of these studies found that issues such as
population movement, changing food supply, relations between
drug distributors and targeted groups, rumours and conspiracy
theories about the ‘‘real’’ purpose of treatment, subjective
experiences of side effects from treatment, alternative understand-
ings of affliction, responses to social control measures, and
historical experiences of public health control measures all made
a huge difference. These papers highlight the need to adapt MDA
to local circumstances. It also points to issues that can be
generalised, notably with respect to health education, drug
distribution, and more effective use of existing public health
legislation. The authors concluded that current standard practices
of monitoring, evaluation, and delivery of MDA for neglected
tropical diseases (NTDs) are inconsistent and inadequate.
Furthermore, efforts to integrate programmes can exacerbate the
difficulties. Improved assessment of what is really happening on
the ground is an essential step in achieving long-term overall
reduction of the NTD burden for impoverished communities.
The use of IVM in areas where loiasis (caused by another filarial
parasite, Loa loa) is co-endemic can be contra-indicated due to rare,
yet severe adverse events (SAEs), including fatalities [37]. Not all
people with heavy L. loa infections experience SAEs, and further
research is needed to understand factors that predispose some
individuals to SAEs [38,39]. This knowledge is important not only
to avoid the incidence of SAEs but also because MDA
programmes using IVM (onchocerciasis and LF) are not being
conducted in regions with heavy loiasis (see [40] for discussion).
Another notable gap is the lack of safety data and an
appropriate formulation of IVM suitable for administration to
children under 5 years of age and under 15 kg of body weight.
The need for paediatric formulations of anthelmintics has recently
been reviewed [41]. The ability to treat safely small children would
allow community coverage to be increased in MDA programmes.
In some areas, ongoing transmission of filarial infection has been
shown to persist despite more than 20 years of MDA. In some
settings this is likely due to sub-optimal treatment coverage leading
to ongoing transmission; in others a failure to implement effective
vector control measures has impeded control. Other factors
include parasite genetic factors such as heterogeneity in drug
susceptibility, and when this deteriorates with repeated treatment,
the possible development of drug resistance. Priority research
challenges therefore include the implementation of studies
designed to understand the relative contributions of treatment
coverage, compliance patterns, intensity of infection, intensity of
transmission, and parasite genetics/drug resistance on the ability
of individual hosts and their parasites to respond to treatment.
Mass treatment programmes for onchocerciasis and LF are
dramatically reducing transmission and thus morbidity. In some
foci of the Americas, Mali, Senegal, and Nigeria (Kaduna),
encouraging evidence indicates that that elimination of onchocer-
ciasis may be possible using MDA with IVM in settings when high
levels of therapeutic and geographic coverage over many years are
achieved (14 years in Mali and Senegal) [20], initial endemicity
levels are low to moderate, and the competence of the local vector
species is relatively low [42]. Similarly, there are encouraging data
from studies reporting the results of LF elimination programmes in
some parts of the world (e.g., Egypt) [16]. Nevertheless, more
research is needed to evaluate the optimal treatment regimes to
achieve elimination. For instance, in some foci, more frequent
treatment than the standard strategy of annual or biannual MDA
has led to a rapid suppression of transmission even in formerly
hyperendemic communities [43].
Annual treatment of O. volvulus infection with IVM, although
effective in reducing microfilarial load and morbidity, may not be
the optimal treatment schedule for interruption of transmission
and prevention of selection for IVM resistance compared with
more frequent schedules such as biannual treatment, a protocol
that was adopted by the Onchocerciasis Elimination Program for
the Americas (OEPA) in Latin America. More frequent treatment
further reduces microfilarial load and transmission to vectors, and
may therefore reduce the fitness advantage conferred to female
worms that return more rapidly to fertility after IVM treatment.
By contrast, the logistics of providing biannual treatment, and its
possible effect of increasing the rate of selection for resistance (the
simple argument that more frequent treatment would increase the
pressure to select for resistant worms), may mean that annual IVM
treatment is a better option. These are important research
questions yet to be addressed. Studies to address this issue need
to be undertaken in more than one setting, firstly where no or few
rounds of IVM treatment have been dispensed, and thus no
existing selection for drug resistance has occurred, and secondly
where there have been many rounds of IVM treatment and there
is evidence of a sub-optimal response.
Soil-Transmitted Helminthiases
Interventions for the control of STHs entail MDA and/or
individual chemotherapy, as well as improved sanitation, envi-
ronmental conditions, and education. MDA programmes for
STHs are most often directed at school-aged children as they are
the population group most at risk of acquiring heavy infection and
developing associated morbidity, and are most accessible for
intervention through school-based programmes. However, some
MDA programmes are directed at whole communities in highly
endemic areas. The scale of MDA interventions for STHs has
increased significantly in recent years and active surveillance for
adverse events is warranted, although most will be mild.
In contrast to the programmes for filariasis, the focus of MDA
programmes for STHs is to achieve long-term reduction in
infection prevalence and intensity, and consequently of the
associated morbidity, rather than aiming for elimination of
infection. The health outcomes aimed for in STH programmes
are closely related to those of poverty reduction, and improve-
ments in education and sanitation. The apparent limitations of
MDA programmes based on single dose anthelmintic monother-
apy for STHs have been highlighted recently [44]. Although single
dose therapy with either ABZ or MBZ is currently highly effective
against A. lumbricoides, this is not the case for hookworms and
whipworms (Table 2). As highlighted in the review by Geary et al.
[45], one priority research need is to undertake well designed dose-
finding studies to optimise the dose regimes of existing drugs used
for treatment of STHs. Recently, the genetic polymorphisms in b-
tubulin, which cause benzimidazole resistance in livestock
parasites, have been found in T. trichiura and N. americanus. Part
of the cause of the low/variable efficacy of ABZ or MBZ in T.
trichiura and N. americanus may be due to benzimidazole-resistant
genotypes in these parasites in some populations [46]. This needs
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jeopardise the sustainability of control efforts against STHs. DNA-
based assays to detect the occurrence of these single nucleotide
polymorphisms (SNPs) have been developed so that resistance-
associated SNPs can be monitored in stool samples of STH eggs
[47]. Routine M&E should be essential components for all
deworming programmes.
Schistosomiasis
Interventions for the control of schistosome infections involve
MDA and/or chemotherapy of individuals, as well as improved
sanitation, environmental modifications to reduce exposure to the
snail intermediate hosts and to cercariae that have been shed by
snails, and education to reduce unsafe water contact. Schistoso-
miasis control programmes under the umbrella of the Schistoso-
miasis Control Initiative (SCI) (Table 1) are making progress
towards the reduction of prevalence and intensity of infection and
morbidity in Sub-Saharan Africa, with encouraging results from
Mali, Burkina Faso, and Uganda [48–50]. In the latter, reductions
in incidence have also been demonstrated, bringing benefits not
only to those treated but also to those untreated members of the
communities [21]. Spatial mapping of schistosomiasis has been
significantly advanced in both West and East Africa [51,52].
Operations research has highlighted the potential of lot quality
assurance (LQA) sampling for identifying high risk communities
for S. mansoni [53]. PZQ is virtually the only anti-schistosome
medication used in MDA programmes. The development and
thorough evaluation of a paediatric formulation of PZQ would
allow greater population coverage in MDA programmes [54].
An interesting finding has been the recent demonstration that
artemisinin-based compounds (e.g., artemether) are active against
immature stages of schistosomes, which are relatively refractory to
PZQ [55]. The artemisinins could prove useful should PZQ
resistance become a problem. However, because the artemisinins
are currently critically important for malaria chemotherapy (in
light of resistance to most other antimalarials), artemisinins are not
being used for anti-schistosome MDA. Nevertheless, experimental
studies on the possible use of artemisinins, alone or in combination
with PZQ, could be undertaken should concerns about selecting
for artemisinin resistance in malaria diminish. Artemisinins (or an
arteminisin-PZQ combination) could be developed as an arm of
improved chemotherapy for schistosomiasis.
Although rodents can harbour S. mansoni, S. haematobium does
not have non-human reservoirs, which facilitates control.
Occasional infections with S. bovis in situations of very close
proximity between humans and cattle have been reported [56].
Schistosoma japonicum, by contrast, is a zoonosis, and there have
been important recent scientific advances in identifying which
vertebrate species play important roles in transmission among
themselves and to humans in China [57,58] and the Philippines
[59,60]. Cattle and water buffalo may play a major role in the
transmission of S. japonicum to humans in China and the
Philippines [61,62]. In Samar Province in the Philippines, an
association exists between the intensity of infection of dogs and
cats and infection in humans. Treatment or vaccination of
reservoir hosts (e.g., bovines) should be implemented as part of
the control programmes. In fact, an anti-schistosome fecundity
vaccine with an efficacy of 50%–90% is being tested for bovine
vaccination [63].
Food-Borne Liver, Lung, and Intestinal Flukes
Besides PZQ treatment of individuals infected with Clonorchis
sinensis, Opisthorchis viverrini, Op. felineus, Paragonimus spp., Fascio-
lopsis buski, Echinostoma spp., Heterophyes heterophyes,a n dMetagon-
imus yokogawai,t h e r ea r eM D Ap r o g r a m s ,u s i n gP Z Q ,i nE a s t
Asia for clonorchiasis and opisthorchiasis [64]. Triclabendazole
is the drug of choice for fascioliasis [65]. Recognition that liver
fluke infection, caused by Op. viverrini, can be a significant cause
of hepatic cancer has been an important scientific advance [66].
The hepatobiliary changes caused by Op. viverrini usually reverse
after PZQ chemotherapy. However, resolution of hepatobiliary
disease does not occur in all persons after the flukes have been
eliminated. Problematically, these individuals may be at
increased risk of cholangiocarcinoma [67]. In any event, upon
parasitological diagnosis of liver fluke infection, immediate
treatment with PZQ is indicated to eliminate long-lived,
carcinogenic parasites [68]. A more aggressive education
programme in Southeast Asia (to discourage consumption of
raw fish and improved sanitary and food hygiene practices) could
produce long-term reductions in liver fluke–induced morbidity
and mortality. This will involve a greater recognition of the
importance of these infections and greater efforts to prevent
infection.
Table 2. Cure Rates (%, Mean (Range)) of Anthelmintics against Soil-Transmitted Helminths.
Drug Dose
Ancylostoma duodenale and
Necator americanus
(hookworms)
a
Trichuris trichiura
(whipworm)
Ascaris
lumbricoides
(roundworm)
Enterobius
vermicularis
(pinworm)
Strongyloides
stercoralis
(threadworm)
Albendazole 400 mg 72
(59–81)
28
(13–39)
88
(79–93)
—
(40–100
b)
—
(17–95
b)
Mebendazole 500 mg 15
(1–27)
36
(16–51)
95
(91–97)
96
b
—
44
b
—
Ivermectin 200 mg/kg —
(0–20
b)
—
(11–80
b)
50–75
b —
(61–94
b)
—
(83–100
b)
Pyrantel 10 mg/kg 31
(19–42)
—
(0–56
b)
88
(79–93)
.90
b
—
—
Levamisole 2.5 mg/kg —
(66–100
b)
—
(16–18
b)
86–100
b ——
Adapted from [44] and
b[139]. Means are available when meta-analysis of drug efficacy has been conducted and the figures in brackets are confidence intervals.
Otherwise ranges are reported.
aAn. duodenale is usually more susceptible to most anthelmintics than N. americanus.
bIndicates range or single value.
doi:10.1371/journal.pntd.0001549.t002
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The control of taeniasis/cysticercosis is undertaken either by
detection and treatment or MDA programmes. In addition, mass
treatment of pigs as reservoir hosts of T. solium is being undertaken
[69,70]. Treatment of individuals with neurocysticercosis using a
course of ABZ, over several days, kills parasites residing in the
brain, but there is a risk when treating a viable brain cyst that
inflammation could occur and trigger seizures [71] if not
undertaken under appropriate medical supervision. Many people,
in cysticercosis-endemic regions, are given MDA with ABZ or
PZQ for other helminth infections, and there is a theoretical risk
that these anthelmintics could precipitate seizures in individuals
with occult neurocysticercosis. Prevention and control of Taenia
infections should include enhanced sanitation and health educa-
tion (to improve sanitary and food hygiene practices). These
measures by themselves, however, are unlikely to be sufficient for
control of taeniasis/(neuro)cysticercosis, and thus interventions
including human chemotherapy, porcine chemotherapy, or
porcine immunisation are required. Control of Taenia infections
has greatly improved with the introduction of concomitant porcine
mass chemotherapy using oxfendazole, and the development of
TSOL18 as a highly effective porcine vaccine [72]. Proof of
concept of the feasibility of actively eliminating T. solium
transmission has also been provided in recent years in endemic
areas of Peru and in Cameroon [69,70]. The World Health
Organization (WHO) has included taeniasis/cysticercosis in its
Global Plan to combat Neglected Tropical Diseases 2008–2009,
using new initiatives addressing integrated control of zoonotic
diseases and in assessing the burden of food-borne disease.
Co-Endemicity, Polyparasitism, and the
Integration of Intervention Measures
Co-endemicity and polyparasitism are common in poor
countries of the tropics and sub-tropics, the former meaning that
a country or an area within a country (at a region or district level)
can be endemic for more than one infection, and the latter
meaning that the individual host/host populations may harbour
more than one parasite species. This distinction is important for
integration of control interventions at different geographical scales
(from the country level to the community level), to determine the
degree of true overlap of infections and the delineation of
appropriately integrated control strategies [73]. Currently avail-
able single drug treatments can be integrated to target as many as
four of the helminth NTDs, including onchocerciasis, LF, STHs,
and schistosomiasis, by simultaneously administering for example,
PZQ, ABZ, and IVM to communities where these helminth
diseases may co-exist. In practice, different ecological require-
ments by the parasites and/or their vectors (e.g., fast flowing [lotic]
water bodies for onchocerciasis as opposed to slow [lentic] water
bodies for schistosomiasis) may translate into a lesser degree of
overlap at the community level. Experience indicates that the co-
administration of these three anthelmintics does not pose any
significant concern of increased drug toxicity [65]. Nevertheless,
there is evidence in both veterinary nematode parasites and O.
volvulus that prolonged IVM treatment may select on the b-tubulin
gene and increase the rate of selection for benzimidazole resistance
[74–76]; thus, monitoring for resistance development should be
undertaken in any integrated programmes that may be imple-
mented. More operational research is needed to determine the
best implementation strategies for providing drug therapies at
regional and population levels [24], and to investigate the effects of
integration on the achievement and maintenance of optimal
coverage levels, treatment frequency, and treatment duration for
each of the infections incorporated into the integrated strategy.
Studies are required in the affected regions to identify practical
methods to coordinate and execute the proposed treatment plans.
Implementation of any helminth control programme at the
country level will be best developed if strong links are created
with existing interventions. An example of a process that can be
implemented is to add anthelmintic treatment to well-established
vaccination programmes. As there may be significant disparities
between the age (or occupational) groups targeted for onchocer-
ciasis, LF, STHs, and schistosomiasis, studies are necessary to
identify optimal and common age groups for integrated control,
where feasible. There is still the need to face additional political
hurdles in order to facilitate groups that work with different
diseases, and follow different protocols, to cooperate on disease
control efforts and to fully integrate their activities.
The concept of integrating NTD management should go
beyond anthelmintic chemotherapy as the only solution. As an
example, Gray and coworkers [77] have pointed out that over
US$350 million, until 2013, has been committed by donors for
schistosomiasis control, relying almost exclusively on PZQ.
However, chemotherapy by itself is not sufficiently effective, and
sustainable donor funds should be spent on developing a multi-
faceted, integrated programme of control, possibly involving a
transmission-blocking vaccine, among others. Longer-term goals
should include vaccine development, morbidity control, and
suppression of transmission of these diseases as well as the
development of better and more sensitive monitoring prior to and
after chemotherapy (including those untreated/unvaccinated
sections of the population in order to ascertain reductions in
environmental transmission), and the improvement of hygiene,
housing, and sanitation conditions, which will help with the
sustainability of the achievements attained. A truly integrated
management plan should therefore also include fundamental
public health measures such as access to clean and potable water,
adequate sanitation, waste disposal and improved environmental
conditions, housing, and health education.
Moreover, as control programmes targeting a number of
infectious diseases become integrated, co-formulation of pharma-
ceuticals could be advantageous. This will necessitate controlled
studies of drug combination safety, and enhanced pharmacov-
igilance. In addition, if dose rates or formulations are changed to
optimise antiparasitic efficacy, pharmacovigilance will become
crucially important.
The Need for Optimising Existing and Developing
Novel Intervention Tools
Optimisation of Existing Drugs
It is important to recognise that drug treatment regimes in
helminth control strategies have generally not been optimised for
treatment of human populations [45], let alone in integrated
programmes for multiple NTDs, in which drug combinations need
to be co-administered simultaneously or in staggered protocols.
Very often, dose rates have been extrapolated from veterinary
studies and treatment regimes have been designed to reduce the
need for repeat treatment, or adopted following the dose rates used
for other infections in drug donation programmes that expand
their goals towards other infections. From the point of view of
large-scale and community-directed anthelmintic delivery, as well
as from the point of view of the companies manufacturing the
pharmaceuticals, these may be important and practical consider-
ations. However, as discussed above, sometimes the resultant drug
efficacy is not optimal. This can have the consequences that the
level of control/transmission interruption that is achieved is sub-
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develop. A related problem is that it is often difficult to assess
accurately the efficacy of anthelmintics used against human
parasites. Reliable biomarkers that could quantify parasite burdens
could greatly assist with assessing efficacy, and this constitutes an
important research challenge. Experiments involving parasite-
animal models, followed by correlation studies between the
biomarkers and existing means of assessing anthelmintic efficacy
in humans, such as egg count reductions, would be required to
validate such biomarkers.
As an example of the above mentioned problem with dose rates
that are adopted from a drug donation programme for one disease
to the expansion of such a programme to another disease, the
dosage of IVM in the IVM + ABZ treatment used for LF control
may be sub-optimal (the 150 mg of IVM per kg of body weight that
is standard for onchocerciasis may not be the best for LF [45]).
Optimisation of dose rates for these drugs will require additional
research. In addition, yearly treatment has been followed for
logistical reasons to attempt to achieve LF elimination. It is likely
that more frequent treatment (6–9 months) with either DEC, DEC
+ ABZ, or IVM + ABZ would have a greater effect on suppression
of transmission and shorten the time for elimination to be achieved
(an area of research where mathematical modelling could assist
greatly [78]). In addition, the advantages of more frequent
treatment with ABZ (and IVM) on reducing morbidity due to
STHs, as a collateral benefit of treatment for LF, may be greater
than those achieved with annual treatment. With all of the
helminth diseases of humans, there is a paucity of pharmaceuticals
available, and this is of concern in view of the increasing
deployment of large-scale mass administration programmes with
the existing few drugs and the increased possibility of drug
resistance development.
In the case of schistosomiasis, use of the levo-racemer allows a
lower dose rate to be used, compared to the standard PZQ, which
is a racemic mixture in which the d-PZQ has almost no effect [79].
However, little research has been undertaken on this topic in
recent years.
Anthelmintic Combinations
There are two reasons for considering the use of combination
anthelmintics; firstly, to increase the spectrum, effectiveness, and
convenience of drug administration, and secondly, to slow the
development of resistance. In the first instance, two different
anthelmintics might be given in order to integrate control
programmes, e.g., schistosomiasis control with that of STH in
school children, with PZQ and ABZ. The safety of combining
ABZ + PZQ has been demonstrated [80,81], and it is of interest
that this combination increases the serum levels of ABZ
sulphoxide. Alternatively, two anthelmintics may be given together
(as separate medications or as a co-formulation) in order to
increase the effectiveness of the drug treatment. Examples of this
include the co-administration of ABZ with PZQ for neurocysti-
cercosis, or ABZ with DEC (or IVM) for LF. In the latter example,
the DEC (or IVM) exhibits microfilaricidal activity, has some
limited adulticidal activity (in the case of DEC), and causes a
temporary inhibition of reproduction by the adult parasites (IVM
and DEC), while the ABZ extends the duration of inhibition of
reproduction and exerts activity against some STHs as a collateral
benefit. These extensions of the spectrum or effectiveness of
chemotherapy may be desirable in their own right. Limited
research has been done to assess whether combinations of different
anthelmintics produce synergistic effects. Some evidence of
synergy has been reported with combinations of artemisinins or
synthetic peroxides with either PZQ or tribendimidine against C.
sinensis [82], or with triclabendazole against F. hepatica [83]. Using
the Caenorhabditis elegans model, significant synergy was reported
between Cry proteins from Bacillus thuringiensis and the nicotinic
acetylcholine receptor (nAChR) agonists tribendimidine and
levamisole [84]. There is a need for more research to investigate
whether combinations of different anthelmintics can bring
significant synergies and improve control of helminth infections.
Combination chemotherapy is often suggested as a means of
reducing selection of drug resistance. Drug resistance is recognised
as a major hindrance to the control of many of the important
infections, including malaria, tuberculosis, and HIV. Drug
combinations, rather than monotherapy, are accepted as the best
approach to treat all three diseases, with for example, the use of
artemisinin-based drug combination now recommended by the
WHO for malaria. The use of combinations to delay the
development of anthelmintic resistance should be a research
priority so that appropriate combinations are used and optimised
for this purpose. In the treatment of veterinary parasites, the use of
anthelmintic combinations to slow the development of resistance
has been promoted in Australia and New Zealand [85,86] but
remains controversial [87,88]. A number of conditions will
determine whether combination chemotherapy will be better than
monotherapy in slowing the development of resistance. Combi-
nations will be most beneficial when: (i) resistance mechanisms, to
the different anthelmintics in the combination, are under
independent genetic control, i.e., do not share common mecha-
nisms of resistance/resistance genes; (ii) resistance mechanisms are
functionally recessive at the dose rates used; (iii) the genes for
resistance are rare and the efficacy of each of the component
compounds against the parasite population approaches 100%; (iv)
a proportion of the population is not exposed to treatment, i.e.,
some refugia exist; and (v) the compounds used have similar half-
lives [87–89].
However, at the current time, we may be far from these ideal
situations in controlling helminth infections in humans. For
example, some anthelmintics from different chemical classes may
share similar resistance mechanisms and select on the same genes.
There is a considerable literature indicating that ABC transporters
are involved in IVM resistance (see [90] for review). However,
benzimidazole anthelminthics may also select on some ABC
transporter genes [91,92]. Furthermore, changes in the isotype b-
tubulin gene are known to cause benzimidazole resistance [93],
while IVM also selects on the isotype 1 b-tubulin gene of some
nematode parasites [74–76]. Thus, a combination of ABZ and
IVM may be useful in terms of broadening the spectrum/efficacy
of the combination, compared with each anthelmintic individually,
but it may not reduce the rate of selection for resistance to one or
both components of the combination. While there is no evidence
that benzimidazole resistance causes cross-resistance to IVM,
there is now some evidence that selection with IVM can select for
benzimidazole resistance [76]. The other condition that appears to
be problematic for the use of anthelmintic combinations for
human helminth infections, in terms of delaying selection for
resistance, is that the efficacy of current drugs used against human
helminths is often not close to 100%. These examples highlight the
importance of assessing any proposed combination against the
criteria outlined above before recommending a combination as a
means of delaying the selection for resistance. Nevertheless, there
will likely be a role for combinations to expand spectrum or
efficacy, as well as to provide increased convenience for MDA
programmes. In addition, it is obvious that the co-administration
of two anthelmintics should not result in increased side effects or
toxicity. In this regard, it should be noted that some anthelmintics,
such as IVM, are very potent inhibitors of ABC transporters [90]
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the host and in the parasite, of other pharmaceuticals that are
substrates for the same ABC transporters, and thus potentially
increase toxicity to the host (undesirable) or to the parasite
(desirable). Thus, research should be undertaken on possible
interactions and selection on resistance mechanisms of possible
combinations.
New Drugs
There is a critical need for new anthelmintic drugs to be
developed for human use. New anthelmintics for STHs, such as
tribendimidine (which shares a mechanism of action with
levamisole and pyrantel) [94], and nitazoxanide, do not appear
to have superior efficacy against nematodes, compared with those
commonly used and shown in Table 2. However, the opisthorch-
icidal activity of tribendimidine should be noted [95]. Research is
required to assess the use of these new anthelmintics for MDA of
STHs and possibly for food-borne trematodiases. The desirable
characteristics for a new anthelmintic against STHs are outlined,
as an example, in Table S1. Most of the existing anthelmintics
used in human medicine were initially developed for parasite
control in animals, where there is a significant commercial market.
New veterinary anthelmintics (e.g., emodepside, derquantel)
should be evaluated for potential use against helminth parasites
of humans (see [2,65]). Monepantel has been evaluated for its
activity against STHs, but cannot be recommended [96]. In the
current market-based system for drug development, registration,
and marketing it is unlikely that pharmaceutical companies on
their own will develop anthelmintics uniquely for human use.
Nevertheless, pharmaceutical companies have been willing to
work with public bodies and philanthropic foundations to develop
anthelmintics for human use where the cost of such development is
shared. In this way pharmaceutical companies can bring their
considerable experience in drug discovery, screens, and chemical
libraries to bear in the search for new anthelmintic molecules.
Moxidectin is under development for use in humans for the
treatment of onchocerciasis [97]. Studies in model filarial
infections and Phase 2 studies in individuals with O. volvulus
indicate that it may result in a significantly greater suppression of
microfilarial production by the adult parasites, maintaining the
microfilaridermia at very low levels for up to 18 months. If this
were confirmed in human clinical studies, treatment with
moxidectin could be advantageous for onchocerciasis control
compared with IVM. The development of IVM resistance in O.
volvulus [98] could, however, possibly compromise moxidectin, as
these two macrocyclic lactone anthelmintics appear to share (in
veterinary nematodes) some, but not a complete set, of resistance
mechanisms [99], and this requires investigation in populations in
which there may be IVM-resistant parasites. If the apparent
advantages of moxidectin for onchocerciasis control are con-
firmed, consideration should be given for its use against LF. In
veterinary use, long-acting formulations of moxidectin have been
developed and show significant therapeutic advantages against
filarial parasites. Thus, long-acting formulations for human use
should be considered if current development efforts with
moxidectin prove successful. Not-for profit organisations such as
the Drugs for Neglected Diseases initiative (DNDi), with Michigan
State and McGill University, have begun to evaluate flubendazole
as a macrofilaricide for LF and onchocerciasis [100].
Another potential new drug development strategy is the possible
use of antibiotics to target the Wolbachia endosymbionts in O.
volvulus and W. bancrofti. However, at present the recommended
antibiotic, doxycycline, seems unlikely to be suitable for large-scale
mass chemotherapy due to the long course of daily treatment
required to obtain desirable effects (6 weeks), and the fact that this
drug is contraindicated in young children and pregnant or
potentially pregnant women. Field trials have been conducted to
test the feasibility of administering doxycycline via community
distributors with good coverage and compliance in areas endemic
for both onchocerciasis and loiasis [101]. A 6-week course of
doxycycline has a marked macrofilaricidal effect. Given that L. loa
is one of the filarial parasite species that lacks Wolbachia
endosymboints, anti-Wolbachia therapy may be an attractive
approach in those endemic areas where IVM cannot be used
because of the possibility of life-threatening adverse reactions.
Research is currently underway to identify alternative antibiotics
that exert an anti-Wolbachia effect with a shorter course of
treatment [102]. Continued efforts should be made to develop
more effective antifilarial anthelmintics, and particularly to find
drugs with macrofilaricidal activity.
Novel Vaccines
Efforts to develop anti-helminth vaccines have gone on for
many years and continue with steady progress in identifying
candidate antigens, recently aided with the generation of a
number of helminth genomes [103]. The successful TSOL18
porcine vaccine for cysticercosis [104] shows that it is indeed
possible to create a highly effective vaccine against a multicellular
parasite. Proof of concept of the feasibility of actively eliminating
T. solium transmission in a wide endemic area of Peru and in
Cameroon has been provided [7,69,106]. Although it is very
expensive to develop a vaccine for use in humans, in view of the
very high efficacy and safety of the TSOL18 vaccine in animal
models and the very serious morbidity caused by neurocysticer-
cosis in humans, it would be desirable to assess the potential for
using TSOL18 for prevention of Taenia infections in humans. For
this, and other human helminth infections, efforts to increase
vaccine efficiency and to provide long-lasting protection must
continue. There have been some promising leads for the
development of vaccines against human hookworm, onchocerci-
asis, schistosomiasis, and fascioliasis [107–113]. Particular atten-
tion is being paid to helminth proteases and animal model studies
have shown promising results. In addition to efforts to develop
vaccines that could be used for prophylaxis of helminthiases,
current thinking includes using vaccines together with anthelmin-
tics, as adjunct prophylaxis [114]. Such a strategy provides a novel
revitalising concept in a field where control activities have
remained exclusively focused on morbidity reduction using drug
delivery [103]. The development of anti-helminthic vaccines that
do not necessarily induce sterilising immunity could still reduce the
likelihood of vaccinated individuals developing severe infections
and thus reduce the burden of disease. Not only could vaccine-
linked chemotherapy reduce overall morbidity, but it could also
reduce rates of parasite infection and re-infection. This, in turn,
could prolong the interval between repeated drug treatments and
reduce the likelihood of selecting for anthelminthic resistance
[115,116].
Monitoring and Evaluation
M&E should be an integral component of large-scale interven-
tions, but is unfortunately sometimes inadequately pursued. When
the intervention involves repeated use of anthelmintic drugs, the
clinical and parasitological impacts of the treatments, including
impacts on transmission of the parasite and possible adverse
events, should be monitored to assess the effectiveness of the
programme, as well as any possible side effects of repeated drug
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infections are discussed in McCarthy et al. [117].
Whereas age-targeted chemotherapy programmes aim to
control morbidity, parasite elimination will require prolonged
mass treatment of all those infected at all levels of endemicity. This
strategy will substantially shrink the size of susceptible parasite
refugia (populations of untreated parasites, not subjected to
chemotherapeutic pressure), thereby increasing selection pressure
for anthelmintic resistance. It is important therefore that parasite
elimination programmes that rely on chemotherapy put in place
careful surveillance systems for prompt detection of transmission
resurgence and monitoring of drug susceptibility.
Monitoring for Emergence of Drug Resistance
Most helminth control programmes today concentrate heavily
on anthelmintic treatment. Unfortunately, MDA programs are
often less effective than originally planned and, depending on the
initial disease prevalence, need to be continued for longer than
initially anticipated, a situation that risks the development of drug
resistance [118]. Examples of this need to extend MDA
programmes include the extension of APOC from 2010 to 2015
after 15 years of operation, and the need to extend LF elimination
programmes beyond the 4–6 years originally proposed [119].
Review of the Pacific LF Elimination Program [120] after 7 years
of MDA with DEC + ABZ revealed that, while there had been
successes, the goal of elimination had not been achieved and there
was a need to extend the programme beyond the projected 2010
end date. In a study in south India [5], it was reported that despite
20 years of DEC-fortified salt and MDA with DEC, it is possible to
identify individuals with microfilaraemia, albeit much reduced
from pre-intervention levels. What is typically seen is a pattern of
rapid decline in infection intensity levels, followed subsequently by
a decline in prevalence levels in the first few years after
commencement of the MDA programme. This pattern is well
illustrated in the assessment of Global Programme to Eliminate
Lymphatic Filariasis (GPELF) programmatic data available to the
WHO from 20 countries and presented by Ottesen et al. [121],
where it was reported that microfilaremia prevalence decreased
dramatically with four rounds of MDA. However, beyond the
fourth round of treatment, the rate of decline did not appear to be
sustained and entered a relatively static period during which
prevalence remained low, but did not approach zero as originally
predicted. Furthermore, it is important to analyse such data at
individual examples and not at averages, because it is in the outlier
responses that signals of the potential development of drug
resistance can be found.
The need to extend MDA programmes or to explain
unsatisfactory results is often attributed to inadequate coverage
(MDA programme factor), and this certainly can play a key role
and does need examination. However, other explanations also
should be considered, including the quality of the drug
(pharmaceutical factors), the possibility that some individuals have
compromised immunity (individual host factors), or the possibility
that the parasite is not responding normally, such as is seen when
drug resistance is selected or a particular parasite population is less
responsive than populations seen elsewhere (tolerance or natural
resistance in a sub-population of the parasite) (parasite factors).
Where possible, all possible explanations should be examined, and
some, such as coverage and response to treatment (possible
resistance), should be monitored on an ongoing basis. In addition,
the mathematical models that have been developed (see [78]) may
need to be updated to reflect field experience after some years of
efforts to eliminate helminth infections.
It is difficult to obtain reliable phenotypic evidence of
anthelmintic resistance because of the mediocre efficacy of
anthelmintics against T. trichiura, hookworms [3], W. bancrofti,
and O. volvulus [45]; the fact that these parasites cannot be easily
cultured in vitro under conditions that would mimic the in vivo
effects of the drugs, or in animals that provide realistic models of
infection in humans; the difficulties in sampling adequately for the
target stages of the drugs, and because density-dependent
processes may affect interpretation of post-treatment egg counts
or skin/blood mf counts. In nematode parasites of farmed animals,
there is a serious problem of anthelmintic resistance to all available
anthelmintics that are used in humans (except DEC, which is
rarely used in animals) [122]. Nevertheless, in parasites of
veterinary importance, phenotypic evidence of resistance often
goes undetected, and it has been estimated that the resistance level
must reach at least 25% before resistance can be detected with
conventional parasitological tests such as faecal egg count
reduction tests for assessing anthelmintic efficacy against STHs
[123]. This same insensitivity also exists with assessment of drug
efficacy in human STHs. The possibility that anthelmintic
resistance will develop in STHs, the limitations of current methods
for its detection, and new biological and molecular assays for
resistance have recently been reviewed [3].
There have been periodic indications of poor DEC efficacy
against LF. Persistence of LF microfilaraemia has been reported in
Haiti after DEC treatment [124,125]. More recently, a sharp
decline in all therapeutic indices with the mf count returning to
pre-treatment levels by the fourth year of single annual DEC
therapy was reported [126]. Even after 20 years of DEC, LF
microfilaraemia may persist [6]. We do not have a test for possible
DEC resistance and do not know whether these and other reports
of unsatisfactory responses to MDA with DEC monotherapy
could, in part, be due to DEC resistance. IVM resistance is now
widespread in nematode parasites of farmed animals, and there is
increasing evidence that it may have developed in some O. volvulus
populations [104]. There is also recent evidence of IVM resistance
emerging in the related filarial parasite Dirofilaria immitis in dogs
[127–130]. So the possibility must be considered that IVM
resistance could also develop in LF and should be monitored.
The persistence of O. volvulus skin mf, which could not be
accounted for by new infections, after many treatments with IVM,
has been reported [98,131]. This is manifested as a greater ability
of the adult female worms to recommence reproduction soon after
IVM treatment than had been observed previously. There is a
need to develop molecular marker(s) for IVM resistance in O.
volvulus populations and to use such marker(s) to monitor, on an
ongoing basis, for possible IVM resistance in areas under MDA
with IVM.
The presence of schistosome populations that are apparently
refractory to PZQ has been reported from time to time in different
parts of the world [132]. Generally, 10%–20% (but the proportion
may be higher in some cases) of infected patients will continue to
excrete eggs after treatment. It was not understood to what degree
this represented selection of a resistant population or incomplete
elimination due to the presence of immature worms at the time of
treatment. In a recent study, a population genetics approach was
used to determine whether or not persistent S. mansoni were drawn
from the same population as susceptible parasites [133]. The
results showed that the persistent parasites were not selected by
PZQ treatment, suggesting that they were not resistant parasites
but were more likely to be derived from immature worms, at the
time of treatment, which were not cleared by PZQ. Nevertheless, a
persistent reduction in efficacy of PZQ in schistosomes would
represent a grave threat to control programmes, as there is a
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resistance in schistosomes should be undertaken as part of large-
scale intervention programmes.
Triclabendazole resistance has become reasonably widespread
in F. hepatica in livestock in developed countries [134] and it could
occur in Fasciola infections in humans. This suggests that
monitoring of treatment outcome is prudent in human fascioliasis.
Elimination
Elimination of the parasites in a region provides the best and
most sustainable outcome of intervention. Elimination of the
infection reservoir is the goal of the GPELF and OEPA, and since
the success story of suppression of O. volvulus transmission in the
Oaxaca focus in Mexico [19] and in Mali and Senegal [20], it is
also an objective for APOC. However, it does need to be
recognised that despite, in many cases, 20 or 30 years of MDA, it
has proven difficult to achieve elimination of onchocerciasis,
STHs, schistosomiasis, and in some situations, LF. As discussed
above, part of the problem is that the tools that we have available
at present are inadequate to achieve elimination for all endemicity
levels. Nevertheless, elimination should remain the ultimate goal of
large-scale intervention efforts. Some of the critical issues that need
to be addressed as we approach elimination are: (i) how to detect
the presence of parasites and active transmission when infection
prevalence and intensity are low; (ii) how to remove persistent low-
level infections despite repeated treatment, and when drug
resistance could be suspected; (iii) when to cease MDA; and (iv)
for how long after apparent elimination should monitoring and
surveillance continue. A discussion of the issues concerning
diagnosis and monitoring can be found in McCarthy et al.
[117], and the role of mathematical modelling in preparing for
elimination in Basa ´n ˜ez et al. [78].
Conclusions
The major multinational pharmaceutical companies provide
many of the drugs used for mass treatment free of charge, or the
drugs are available as low-cost generics, making the MDA
programmes one of the most cost-effective global public health
control measures. MDA programmes have led to major reductions
in morbidity caused by helminth parasites. However, the
sustainability of current interventions has been recently challenged
by the difficulties in maintaining high coverage and compliance
levels and the possible development of drug resistance. Moreover,
the long-term control and elimination of these helminth diseases
will also depend on improved control tools such as more effective
anthelmintics and/or vaccines, control of vectors, intermediate
hosts, or reservoirs, improved diagnostics and surveillance tools,
sanitation, hygiene, socioeconomic improvement, and environ-
mental sustainability of the interventions [135,136]. If they
become available, antiparasitic vaccines could have a major
impact on sustained control of helminth diseases, and could be
combined with MDA to provide complementary approaches that
may improve control and reduce selection for drug resistance.
Vector control, where applicable, practical and cost effective,
remains a useful addition to chemotherapy-based intervention that
can lead to marked reductions in transmission and reinfection
rates. Efforts to integrate various MDA programmes may bring at
first logistical challenges, but in the long-term benefits to the
overall impact of intervention strategies. However, it should also
be recognised that very little funding is available to support the
necessary research. Key recommendations for research to improve
intervention for control and elimination are summarised in Box 2
and a more detailed list of recommendations and gap analysis is
available (see Text S1 for ‘‘Recommendations to Policy and
Decision Makers: Gap Analysis and Identification of Research
Priorities’’). This research is necessary for interventions to remain
sustainable and to achieve elimination of the helminth parasites
that still bring suffering to millions.
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Box 2. Key Research Recommendations
Successful intervention against human helminthiases
depends on optimal utilisation of available control
measures and development of new tools and strategies.
This will require efforts to:
N Optimise existing intervention tools to maximise
impact (including those against polyparasitic infections)
and long-term sustainability. The tools include pharma-
ceuticals, vector control, vaccines, and eco-health
approaches (sanitation, clean water, and increased food
hygiene and education). Sustainability depends on
minimising selection for drug resistance and maintaining
community involvement and participation
N Develop strategies to optimise the delivery, moni-
toring and evaluation (M&E) of multiple interventions
(drug combinations addressed at single or polyparasitic
infections; combinations of antiparasitic and antivector-
ial measures) to various age groups, population levels
(community, district), and geographical scales to maxi-
mise the effectiveness of integrated control
N Develop novel control tools that will improve impact
and sustainability of the interventions, and increase the
possibility of helminth elimination. These tools include
new pharmaceuticals, the development of vaccines,
innovative approaches to vector control, and an
increased understanding of the environmental and social
ecology of these infections
N Minimise the development of anthelmintic resis-
tance, and enhance preparedness. This will require
research and development to:
# Develop assays that can be used to promptly detect
changes in intervention efficacy and investigate the
association of such changes with parasite genetic
and non-genetic factors
# Develop sensitive and efficient tools for resistance
monitoring that can be applied in disease-endemic
countries in operational research settings by control
teams, and be integrated into intervention pro-
grammes as part of M&E
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